Measles-mumps-rubella vaccination at 6 months of age and the risk of atopic disease in the first year of life: Results from a Danish placebo-controlled randomised trial - 05/03/25
, Andreas Jensen b, Michelle Malon a, Jesper Kiehn Sørensen a, Dorthe Maria Vittrup a, Signe Kjeldgaard Jensen c, Emma Therese Bay d, Jannet Svensson e, Lone Graff Stensballe b, fSummary |
Background |
In observational studies, childhood vaccinations have been associated with atopic diseases. However, results are conflicting and evidence from randomised trials is lacking.
Methods |
Atopic disease after interventional measles-mumps-rubella (MMR) vaccine was a pre-planned secondary outcome of the MMR trial, a randomised, double-blind, placebo-controlled trial in 6540 Danish infants in the high-income setting of Denmark. At two hospitals, infants 5–7 months of age were randomly assigned 1:1 to receive an intramuscular injection with M-M-R VaxPro or placebo (solvent only). Randomisation was stratified by site, sex, and prematurity (< 37 weeks of gestation). The infants were followed up in the Danish health registries to detect eczema, asthma-like disease, and allergic rhinoconjunctivitis, the composite outcome of the three diseases being the primary endpoint of the present study.
The trial was registered in the EU Clinical Trials Registry (2016-001901-18) and ClinicalTrials.gov (NTC03780179).
Findings |
Between April 2019 and October 2021, 6540 infants were randomised (3266 MMR and 3274 placebo). There was no difference in the rate of atopic disease before 12 months of age between the MMR and placebo group (76 events MMR vs. 77 placebo), resulting in a hazard ratio of 0·98 (95% confidence interval 0·72 to 1·35). Secondary analyses with follow-up until 24 months of age yielded essentially identical results.
Interpretation |
Based on trial data in 6540 Danish infants randomised to MMR or placebo at 5–7 months, no association between MMR and atopic disease in early childhood was observed.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Measles containing vaccines are linked to atopic diseases in observational studies. |
• | Conflicting results result from lack of evidence from randomised trials. |
• | This randomised trial involved 6540 Danish infants receiving MMR or placebo. |
• | We found no difference in atopic disease rates before 12 months between groups. |
• | The trial showed no association between MMR and early childhood atopic disease. |
Keywords : Vaccination, Measles-Mumps-Rubella Vaccine, Measles, Eczema, Asthma, Hypersensitivity, Child, Infant
Plan
Vol 90 - N° 3
Article 106433- mars 2025 Retour au numéro
Article précédent
- Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study
- Jennifer K. Quint, Sabada Dube, Lucy Carty, Renata Yokota, Samira Bell, Lance Turtle, Yi Lu, Kathryn Evans, Nahila Justo, Michelle Harley, Jurgens Peters, Carla Talarico, Richard McNulty, Ana Goios, Sylvia Taylor, Rachael A. Evans
- Efficacy of oral rinse and other detection methods in detecting oral human papillomavirus infections: The Oromouth cohort study
- Bethany Hillier, Tim Waterboer, Jill Brooks, Paul Nankivell, Ridhi Agarwal, Ahmad K. Abou-Foul, Tessa Fulton-Lieuw, Caroline Kristunas, Alex Vorsters, Joanna Parish, Hisham Mehanna
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?